Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gynagone (also marketed as Gynagone Kit) is a co-packaged syndromic management kit developed and manufactured by Laboratory & Allied. It is approved in East African countries, including Kenya, Rwanda, Tanzania, and Ethiopia, for the treatment of gynecological and vaginal infections (such as bacterial vaginosis, trichomoniasis, candidiasis, and mixed infections). The kit contains three active pharmaceutical ingredients: azithromycin (a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit), fluconazole (a triazole antifungal that inhibits fungal lanosterol 14-alpha-demethylase), and secnidazole (a nitroimidazole antimicrobial that undergoes intracellular reduction to form reactive intermediates that damage microbial DNA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azithromycin + fluconazole + secnidazole (Laboratory & Allied).